At present, it could well be said that Cipla is the leading producer in the world as far as the antiretroviral drugs that fights HIV/AIDS are concerned and this has been estimated on the basis of unites that are produced, distributed and sold by the Cipla. It is required to state here that Cipla neglects foreign patents on these drugs and by adopting this step the, The Chemical Industrial and Pharmeceutical Company reduced the cost associated with the providing of the antiretrovirals to patients suffering from AIDS.
Cipla has recently undergone an agreement with the Akom, a drug firm that belongs to the US. Cipla had announced that they have entered a development as well as a supply deal on a generic anti – organ rejection drug. According to the norms of this deal, Cipla would take upon them the responsibility as far as the production and supply of the drug is concerned, while the Akom would chiefly concentrate on the clinical study to prove the fact or to show that the generic product is bioequivalent to the branded drug and would also be responsible for regulatory and submission of the drug. Although both the companies did not specify on the branded drug on which the generic would be based it has been said that the market size for drug would roughly be $750 million.
usforindians gives all the necessary information on Cipla.
|
